By Colin Kellaher
Merck & Co. has agreed to license an investigational oral small molecule lipoprotein(a) inhibitor from Jiangsu Hengrui Pharmaceuticals in a deal potentially worth more than $2 billion to the Chinese pharmaceutical company.
Merck on Tuesday said it will make an upfront payment of $200 million to Hengrui Pharma to license HRS-5346, which is currently in a Phase 2 study in China for the reduction of lipoprotein(a), or Lp(a), which can accumulate in blood vessel walls and result in conditions such as heart attack, stroke and other cardiovascular diseases.
The Rahway, N.J., drugmaker said Hengrui Pharma will be eligible to receive up to an additional $1.77 billion in payments associated with certain development, regulatory and commercial milestones, along with royalties on sales.
Merck said it will have exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding the Greater China region.
Merck said it expects the deal, which complements its cardio-metabolic pipeline, to close in the second quarter, adding that it will book a charge of about 6 cents a share related to the transaction.
rite to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 25, 2025 07:10 ET (11:10 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。